NCT03781362View on ClinicalTrials.gov

Study of CPI-100 in Patients With Advanced Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 21, 2018

Primary Completion Date

June 21, 2022

Study Completion Date

June 21, 2022

Conditions
Advanced Tumors
Interventions
DRUG

CPI-100

CPI-100 will be administered via intravenous infusion on Day 1 of a 14-Day cycle

DRUG

Capecitabine

Capecitabine will be administered 1000 mg/m2 orally twice a day for 2 weeks followed by a 7-day rest period

Trial Locations (3)

44106

University Hospitals Cleveland Medical Center, Cleveland

49546

South Texas Accelerated Research Therapeutics, Grand Rapids

78229

South Texas Accelerated Research Therapeutics, San Antonio

Sponsors
All Listed Sponsors
lead

Coordination Pharmaceuticals, Inc.

INDUSTRY

NCT03781362 - Study of CPI-100 in Patients With Advanced Tumors | Biotech Hunter | Biotech Hunter